Archive for December, 2016

04 DecThis is an important development.

Katz agreed:.. This is an important development, because we now know one of the main triggers for the spread of this type. . researchers Breakthrough Breast Cancer are excited about this discovery because it already has targeted drugs in development, C35, provides a new treatment for HER2-positive breast cancer. It is exciting to know, a drug a drug that could potentially happen to stop this process, and save the lives of women with breast cancer, said Harrison. We need more work in the lab this concept this concept before we can start doing patient studies, he added.

Katz and colleagues found that:’could C35 functions as an oncogene in breast cancer cell lines Drug Targeting of C35 or Syk kinase be helpful in treating a subset of patients with HER2 – amplified breast cancer. ‘ Professor David Harrison, Director of the Breakthrough Breast Cancer Research Unit at the University of Edinburgh, told the press that:. Read more…

03 DecCan be placed in order to reduce the extent and severity of adhesions that.

About REPEL -CV – form REPEL-CV formed a bioresorbable adhesion barrier film to the surface of the heart surgery to the outcome of open-heart surgery, can be placed in order to reduce the extent and severity of adhesions that. Between the surface of the heart and opposing tissue surfaces after surgery It is designed to perform the task, and then therapeutic degraded so that from the body.

The three scholarships to take four the number of NHMRC Dementia Research Grants awarded to UQ researchers. UQ was grant in the first round of 530 dementia $ 000 into 2007, awarded for a study led by Professor Gerard Byrne in anxiety and depression in people with dementia. Read more…

03 DecThe decrease in pre-bronchodilator FEV1 average not significantly different between groups.

Patients receiving tiotropium were also found to better health have at all times. The risk of an exacerbation was 18 percent for patients the tiotropium were reduced, and patients who tiotropium also saw the risk of hospitalization due to worsening decline of 26 percent. Conclude the authors: ‘In patients with GOLD stage II COPD, long-term treatment with tiotropium appeared to reduce the rate of decline of the post – bronchodilator FEV1 and the risk of exacerbations, lung function also found that the lung function and health. Was better were better in the tiotropium group than in the control group during the whole process the treatment of COPD treating COPD among symptomatic patients with moderate disease. ‘.. The researchers found that the rate of decrease in the mean post – bronchodilator FEV1 per year was 12 percent lower in the tiotropium group than in the placebo group .

Overall, 2376 patients qualified for the final analysis it was , 1218 patients received tiotropium plus. 1158 placebo over a period of four years.. Although the UPLIFT study, patients were examined at all stages of the disease, the authors in this paper a predefined subgroup analysis of patients specifically to GOLD stage II* . Of the total of 5993 patients, 2739 had GOLD stage II COPD at randomization, with a mean age of 64 years. Overall,ronchodilator spirometry was before the administration of study medication in the morning made a clinic visit . Post – bronchodilator spirometry study medication study drug and short-acting bronchodilators . Read more…